SOURCE: Xtalks

Xtalks Webinars

October 01, 2014 08:05 ET

Indirect Treatment Comparisons and Network Meta-Analyses for Managers and Directors: Concept & Application Using a Non-Technical, User-Friendly Tool, Live Webinar Hosted by Xtalks

TORONTO, ON--(Marketwired - October 01, 2014) - This interactive webinar will review the indirect treatment comparison that can be described as a way of pooling clinical evidence to establish the relative efficacy of treatments never compared against each other but compared against a common comparator, without breaking randomization. Join to learn more on Tuesday, October 14, 2014 at 10:30am EDT (NA) / 3:30pm BST (UK GMT +1). 

Following a successful session earlier this year on budget impact analyses, Marie Maxime Hubert, Health Economics and Outcomes Research Manager at JSS Medical Research will be presenting indirect treatment comparisons and network meta-analyses for managers and directors: Concept and application using a non-technical, user-friendly tool. This introductory course is meant to:

 1) Conceptualize indirect treatment comparisons (ITCs)
 2) Recognize the different types
 3) Understand their advantages and disadvantages

The session includes a hands-on workshop using a simple ITC tool requiring no technical experience.

The indirect treatment comparison (also referred to as network meta-analysis and multiple treatment comparison) is a new methodology on everyone's radar as it is in high demand and frequently used by health technology assessment (HTA) agencies, particularly the Canadian Agency for Drugs and Technologies in Health (CADTH).

After the session, attendees will be able to answer the following questions:

  • Do you understand how this new technology might impact clinical development and market access?
  • Can you consider the feasibility of an indirect treatment comparison (ITC) when strategically planning a product's clinical development or market access approach?
  • Can you predict the results of an ITC under the simplest scenario (product A vs. B using their comparison against product C)?
  • Can you integrate the results of an ITC in an economic evaluation and estimate the resulting incremental cost-effectiveness ratio?
  • Can you suggest the optimal inclusion and exclusion criteria of a phase III study design to fit with an existing ITC?
  • Would you be able to interpret and defend the performance of a product in an ITC, or justify why an ITC cannot be performed?
  • Can you recognize a naïve ITC?
  • Can you tell the difference between a network meta-analysis (NMA) and mixed treatment analysis (MTC)?
  • Can you identify which type(s) of ITC can be performed given the available evidence?

This session is geared towards the pharmaceutical industry, specifically managers, directors, and senior executives who are elaborating clinical development or market access strategies. As the session requires no biostatistical or technical expertise, it will provide great value for individuals with no prior knowledge or those who attended a training aimed at performing the complex analytics that left them more puzzled than inspired. No methodology for performing the ITC will be discussed and as such, the session might be unsuited for analysts, biostatisticians or economic modellers. However, during the second half of the session, a hands-on workshop will teach participants how to use a simple ITC tool to estimate outcomes. The tool, compatible with all Windows systems, will be accessible for download at no charge from the corporate website of JSS Medical Research. For the practical portion, prior understanding of effect estimates (hazard ratio, odds ratio, rate difference, etc.) is preferable but not necessary. In brief, the session is ideal for anyone wishing to stay up-to-date on the newest methodologies.

In a nutshell, the indirect treatment comparison can be described as a way of pooling clinical evidence to establish the relative efficacy of treatments never compared against each other but compared against a common comparator, without breaking randomization. For example, if treatment A and treatment B have never been compared in a randomized clinical trial, but they have both been compared to the standard of care, treatment C, in a similar patient population, an indirect treatment comparison anchored on "C" can provide a relative effect estimate of "A" versus "B". Indirect treatment comparisons are particularly useful as more often than not, the phase III clinical trial did not include the relevant active comparator(s). Moreover, in order to obtain more precise estimates, the indirect treatment comparison can be applied using both direct and indirect clinical evidence.

To learn more about this event visit: Indirect Treatment Comparisons and Network Meta-analyses for Managers and Directors

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Image Available:

Contact Information

  • Contact:
    Michelle Tran
    Tel: +1 (416) 977-6555 ext 352
    Email: mtran(at)xtalks(dot)com